Clinical Trial Update: Phase 2 Study of MD-1100 Acetate Administered for 14 Days to Patients Meeting Criteria for Chronic Constipation [Phase 2]

View source ↗

Summary

Phase 2 study of MD-1100 Acetate for chronic constipation has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Constipation

Drugs mentioned

• MD-1100 Acetate (tenapanor)

Snippet

Sponsor: Ironwood Pharmaceuticals, Inc. | Conditions: Constipation | Phase 2 | Status: COMPLETED